Heart failure prevention plan for cancer survivors treated with past chemotherapy
Tests a heart care plan in cancer survivors who had chemotherapy years ago.
Plain-language title generated from the registry record
Registry title: Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
Key facts
- Where
- Melbourne, AustraliaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT04962711, who can take part
Where in Australia
- Baker Heart and Diabetes InstituteMelbourne, AustraliaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Baker Heart and Diabetes Institute
- Trial code
- NCT04962711
- Record updated
- 31 May 2025
- Original description
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors >55 years old with chemotherapy >5 years ago.Read full original descriptionShow less
Risk-guided Disease Management Plan to Prevent Heart Failure in Patients Treated With Previous Chemotherapy (REDEEM)
This is a prospective study in which a process of identifying and reducing heart failure (HF) risk will be applied to cancer survivors >55 years old with chemotherapy >5 years ago.
The overall goal of this study to identify the feasibility and value of risk-guided cardiac rehabilitation (exercise, risk factor modification, and behavioural support) as a component of survivorship care.
Inclusion: History of cancer > 10 years ago; Have received potentially toxic chemotherapy Anthracycline (any dose) Trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR Tyrosine kinase inhibitors (e.g. sunitinib) OR Left chest radiotherapy.
Exclusion: History of previous heart failure (baseline New York Heart Association (NYHA) classification >2); Contraindications to beta blockers or angiotensin-converting enzyme inhibitors; Oncologic (or other) life expectancy <12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial; Already taking both angiotensin converting enzyme inhibitors/angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both; Ejection fraction at baseline echo <50%; Valvular stenosis or regurgitation of >moderate severity; Systolic BP <110 mmHg; Pulse <60/minute if not on beta blocker; Inability to acquire interpretable images (identified from baseline echo); Unable to provide written informed consent to participate in this study.